@Doc, What are you hoping to see from Dr. Sabbagh's presentation? Beyond safety and tolerability, there are a few impactful factors for MAA success, like the efficacy of the S1WT subgroup and OLE 96-week data. Would the SS sig outcome of both primary endpoints of either the S1WT subgroup or OLE change your approval outlook? The S1 activation/correlation and DNA details seem less relevant in the submission.
Yes. (And Sabbagh is busy at this year's conf, with quiet a few companies and studies.) Any disclosures would not happen until our presentation. Let's see if the S1wt analysis makes it through per the poster draft. A little later, any MAA announcement given the EMA schedule.
Immediately following today’s 'Ask the Expert' session will be a perfect time to meet with potential partners for blarcamesine in the EU and the rest of Europe ie the UK etc.
Market Data 
Markets 
AI
